New and emerging lipid-modifying drugs to lower LDL cholesterol.
| Autor: | Kosmas CE; Department of Medicine, Division of Cardiology, Montefiore Medical Center, Bronx, NY, USA.; Cardiology Clinic, Cardiology Unlimited, PC, New York, NY, USA., Pantou D; School of Medicine, University of Nicosia, Nicosia, Cyprus., Sourlas A; School of Medicine, University of Crete, Heraklion, Greece., Papakonstantinou EJ; General Directorate of Public Health and Social Welfare, Attica Region, Athens, Greece., Echavarria Uceta R; Cardiology Clinic, Cardiology Unlimited, PC, New York, NY, USA., Guzman E; Department of Medicine, Division of Cardiology, Montefiore Medical Center, Bronx, NY, USA.; Cardiology Clinic, Cardiology Unlimited, PC, New York, NY, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Drugs in context [Drugs Context] 2021 Nov 01; Vol. 10. Date of Electronic Publication: 2021 Nov 01 (Print Publication: 2021). |
| DOI: | 10.7573/dic.2021-8-3 |
| Abstrakt: | Cardiovascular disease (CVD) represents the leading cause of death worldwide. The role of low-density lipoprotein-cholesterol (LDL-C) in the pathophysiology of atherosclerosis and CVD has been well recognized. Statins are the standard of care for the management of hypercholesterolaemia, and their effectiveness in lowering LDL-C and reducing CVD risk in both primary and secondary prevention has been well established. However, several patients fail to attain optimal LDL-C goals or are intolerant to statins, especially at high doses. PCSK9 inhibitors, bempedoic acid, inclisiran, ANGPTL3 inhibitors, PPARβ/δ agonists and LXR agonists are novel or upcoming LDL-C-lowering agents that have shown promising beneficial results. This review aims to present and discuss the current clinical and scientific data pertaining to the new and emerging lipid-modifying LDL-C-lowering drugs. Competing Interests: Disclosure and potential conflicts of interest: Constantine E. Kosmas and Eliscer Guzman have served as members of the Dyslipidemia Speaker Bureau of Amgen, Inc. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2021/10/dic.2021-8-3-COI.pdf (Copyright © 2021 Kosmas CE, Pantou D, Sourlas A, Papakonstantinou EJ, Echavarria Uceta R, Guzman E.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|